HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

iloperidone

an atypical, negative symptom antipsychotic agent
Also Known As:
Fanapt; HP 873; HP-873; Zomaril; Ethanone, 1-(4-(3-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)propoxy)-3-methoxyphenyl)-
Networked: 106 relevant articles (14 outcomes, 31 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1. Citrome, Leslie: 8 articles (01/2015 - 12/2010)
2. Weiden, Peter J: 7 articles (01/2016 - 04/2008)
3. Wolfgang, Curt D: 6 articles (01/2016 - 03/2008)
4. Meng, Xiangyi: 6 articles (01/2015 - 09/2011)
5. Hochfeld, Marla: 4 articles (03/2014 - 09/2011)
6. Cutler, Andrew J: 4 articles (02/2013 - 04/2008)
7. Tarazi, Frank I: 3 articles (09/2018 - 09/2012)
8. Malhotra, Anil K: 3 articles (02/2014 - 07/2008)
9. Potkin, Steven G: 3 articles (02/2013 - 04/2008)
10. Lavedan, Christian: 3 articles (02/2010 - 03/2008)

Related Diseases

1. Schizophrenia (Dementia Praecox)
2. Psychomotor Agitation (Akathisia)
3. Psychotic Disorders (Schizoaffective Disorder)
07/21/1995 - "Iloperidone is currently used in clinical trials for the treatment of psychoses. "
01/01/2012 - "Consistent with product labeling, iloperidone 10-16 mg/day or 20-24 mg/day demonstrated significant improvement over placebo on BPRSd and PANSS-T scores, as well as on PANSS-P and PANSS-N subscale scores over 6 weeks of treatment in patients with schizophrenia and in the ITT population, which includes patients with schizoaffective disorder. "
01/01/2012 - "We thus conducted an analysis that assessed key efficacy and tolerability outcomes post hoc from four pooled short-term (4-6 weeks) phase III studies that evaluated iloperidone versus placebo in patients with schizophrenia or schizoaffective disorder. "
01/01/2012 - "Patient-level data were pooled from four prospective, randomized, double-blind, placebo-controlled and active-controlled, multicenter trials of iloperidone in patients with schizophrenia or schizoaffective disorder aged 18-65 years. "
04/01/2008 - "The primary efficacy variable was time to relapse, defined as a 25% or more increase in PANSS total score, including at least a 10-point change; discontinuation because of lack of efficacy; aggravated psychosis with hospitalization; or 2-point increase in the 7-item CGI-C after week 6. Of 1644 patients randomized and 1326 completing the 6-week phase, 473 (iloperidone, n = 359; haloperidol, n = 114) were included in the long-term efficacy analysis, and 489 (iloperidone, n = 371; haloperidol, n = 118) in the safety analysis. "
4. Bipolar Disorder (Manic Depressive Psychosis)
5. Catalepsy

Related Drugs and Biologics

1. Antipsychotic Agents (Antipsychotics)
2. Risperidone (Risperdal Consta)
3. ziprasidone (Geodon)
4. Haloperidol (Haldol)
5. Ciliary Neurotrophic Factor (CNTF)
6. idebenone
7. asenapine
8. Lurasidone Hydrochloride
9. Olanzapine (Zyprexa)
10. Aripiprazole (Abilify)

Related Therapies and Procedures

1. Therapeutics
2. Off-Label Use
3. Stents
4. Injections
5. Drug Therapy (Chemotherapy)